NeuroPace Inc.(NPCE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NPCE NeuroPace Inc.

Pre-Market Trading 12-19 05:32:25 EST

10.64

-0.88

-7.64%

盘前11.13

+0.49+4.61%

04:48 EST

High12.23	Low9.92	Vol86.21K
Open11.69	D1 Closing11.52	Amplitude20.05%
Mkt Cap317.58M	Tradable Cap139.26M	Total Shares29.85M
T/O942.80K	T/O Rate0.66%	Tradable Shares13.09M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"NPCE","market":"US","secType":"STK","nameCN":"NeuroPace Inc.","latestPrice":10.64,"timestamp":1734555600000,"preClose":11.52,"halted":0,"volume":86205,"hourTrading":{"tag":"盘前","latestPrice":11.13,"preClose":10.64,"latestTime":"04:48 EST","volume":1,"amount":11.13,"timestamp":1734601681480},"delay":0,"floatShares":13088672,"shares":29848101,"eps":-0.990869,"marketStatus":"Pre-Market Trading","change":-0.88,"latestTime":"12-19 05:32:25 EST","open":11.69,"high":12.23,"low":9.92,"amount":942799.6419,"amplitude":0.200521,"askPrice":16.92,"askSize":500,"bidPrice":10.72,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-0.990869,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1734618600000},"marketStatusCode":1,"adr":0,"listingDate":1619064000000,"exchange":"NASDAQ","adjPreClose":10.64,"preHourTrading":{"tag":"盘前","latestPrice":11.13,"preClose":10.64,"latestTime":"04:48 EST","volume":1,"amount":11.13,"timestamp":1734601681480},"postHourTrading":{"tag":"盘后","latestPrice":10.91,"preClose":10.64,"latestTime":"16:14 EST","volume":1726,"amount":18463.47,"timestamp":1734556493043},"volumeRatio":1.0622161317723342,"impliedVol":0.5224,"impliedVolPercentile":0.2052},"requestUrl":"/m/hq/s/NPCE/tweets","defaultTab":"tweets","newsList":[{"id":"2492993600","title":"NeuroPace Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2492993600","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492993600?lang=en_us&edition=fundamental","pubTime":"2024-12-18 01:32","pubTimestamp":1734456720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NPCE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 17, 2024 12:32 ET (17:32 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NPCE"],"gpt_icon":0},{"id":"2492193403","title":"NeuroPace: Undervalued Innovator in the Drug-Resistant Epilepsy Market with Promising Long-Term Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2492193403","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492193403?lang=en_us&edition=fundamental","pubTime":"2024-12-17 18:37","pubTimestamp":1734431827,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Robbie Marcus maintained a Buy rating on NeuroPace (NPCE – Research Report) today and set a price target of $14.00. Robbie Marc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/neuropace-undervalued-innovator-in-the-drug-resistant-epilepsy-market-with-promising-long-term-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/neuropace-undervalued-innovator-in-the-drug-resistant-epilepsy-market-with-promising-long-term-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NPCE"],"gpt_icon":0},{"id":"2492893408","title":"NeuroPace price target raised to $14 from $9 at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2492893408","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492893408?lang=en_us&edition=fundamental","pubTime":"2024-12-17 18:35","pubTimestamp":1734431723,"startTime":"0","endTime":"0","summary":"JPMorgan raised the firm’s price target on NeuroPace (NPCE) to $14 from $9 and keeps an Overweight rating on the shares following a transfer of ana...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neuropace-price-target-raised-to-14-from-9-at-jpmorgan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neuropace-price-target-raised-to-14-from-9-at-jpmorgan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NPCE"],"gpt_icon":0},{"id":"2492813389","title":"U.S. RESEARCH ROUNDUP- Domino's Pizza, Honeywell, Walmart","url":"https://stock-news.laohu8.com/highlight/detail?id=2492813389","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492813389?lang=en_us&edition=fundamental","pubTime":"2024-12-17 15:19","pubTimestamp":1734419964,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Domino's Pizza, Honeywell, WalmartDec 17 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Domino's","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nL4N3NI0GT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMCSA","PRVA","TOL","BK4121","TMDX","AGL","LU2324357040.USD","HCSG","LW","CMG","LU0889565916.HKD","TXRH","LU1150488135.SGD","IE0008368304.USD","WMT","DPZ","TLRY","COGT","LU2360032135.SGD","ASTH","LU0109391861.USD","POST","RARE","BVS","SNDX","ACI","LU2211815571.USD","WEN","BK4602","JACK","BK4534","NBIX","ZBH","HON","LU1585245621.USD","NPCE","ALEC","PLNT","MOFG","COST","OLMA","RGEN","MD","LU0471298694.HKD","LU2264538146.SGD","BHLB","ALGT"],"gpt_icon":1},{"id":"2491544323","title":"NeuroPace to Host Investor Day on January 28th in New York City","url":"https://stock-news.laohu8.com/highlight/detail?id=2491544323","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491544323?lang=en_us&edition=fundamental","pubTime":"2024-12-13 05:05","pubTimestamp":1734037500,"startTime":"0","endTime":"0","summary":"MOUNTAIN VIEW, Calif., Dec.  12, 2024  (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/12/2996517/0/en/NeuroPace-to-Host-Investor-Day-on-January-28th-in-New-York-City.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4218","BK4211","BK4588","HST","BK4181","BK4539","CHCO","NPCE","BK4585"],"gpt_icon":0},{"id":"2489256149","title":"Wall Street Analysts Think NeuroPace (NPCE) Could Surge 31.47%: Read This Before Placing a Bet","url":"https://stock-news.laohu8.com/highlight/detail?id=2489256149","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489256149?lang=en_us&edition=fundamental","pubTime":"2024-12-06 22:55","pubTimestamp":1733496906,"startTime":"0","endTime":"0","summary":"Shares of NeuroPace, Inc.  have gained 49.2% over the past four weeks to close the last trading session at $11.28, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14.83 indicates a potential upside of 31.5%.However, an impressive consensus price target is not the only factor that indicates a potential upside in NPCE. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. Though a positive trend in earnings estimate revisions doesn't give any idea as to how much the stock could surge, it has proven effective in predicting an upside.That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/e0VWXB5.wUFiKGuJPPpLzg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/e0VWXB5.wUFiKGuJPPpLzg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wall-street-analysts-think-neuropace-145506168.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4082","NPCE","BK4539"],"gpt_icon":0},{"id":"2489714767","title":"NeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2489714767","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489714767?lang=en_us&edition=fundamental","pubTime":"2024-12-05 05:05","pubTimestamp":1733346300,"startTime":"0","endTime":"0","summary":"RNS System to be featured in over 70 scientific presentations and posters Pre-book a demonstration in the NeuroPace Tech Suite to see the latest innovations of the RNS System which simplify the treatm","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/04/2991915/0/en/NeuroPace-to-Showcase-the-RNS-System-at-the-2024-American-Epilepsy-Society-AES-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AES","AFG","NPCE"],"gpt_icon":0},{"id":"2488705669","title":"BRIEF-Neuropace Completes Enrollment In Feasibility Study Of Rns System","url":"https://stock-news.laohu8.com/highlight/detail?id=2488705669","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488705669?lang=en_us&edition=fundamental","pubTime":"2024-12-04 06:46","pubTimestamp":1733265989,"startTime":"0","endTime":"0","summary":"BRIEF-Neuropace Completes Enrollment In Feasibility Study Of Rns SystemDec 3 (Reuters) - Neuropace Inc NPCE.O:NEUROPACE COMPLETES ENROLLMENT IN FEASIBILITY STUDY OF RNS SYSTEM FOR LENNOX-GASTAUT SYNDR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241203:nTUA50LXXF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","NPCE","BK4082"],"gpt_icon":0},{"id":"2488763909","title":"Neuropace Completes Enrollment in Feasibility Study of Rns System for Lennox-Gastaut Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2488763909","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488763909?lang=en_us&edition=fundamental","pubTime":"2024-12-04 05:05","pubTimestamp":1733259900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241203:nTUA50LXXF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","NPCE","BK4082"],"gpt_icon":0},{"id":"2488976421","title":"NeuroPace Completes Enrollment in Feasibility Study of RNS System for Lennox-Gastaut Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2488976421","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488976421?lang=en_us&edition=fundamental","pubTime":"2024-12-04 05:05","pubTimestamp":1733259900,"startTime":"0","endTime":"0","summary":"Enrollment and implant procedures completed in NIH funded feasibility study of LGS, a severe and disabling childhood-onset epilepsyMOUNTAIN VIEW, Calif., Dec.  03, 2024  (GLOBE NEWSWIRE) -- NeuroPace,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/03/2991050/0/en/NeuroPace-Completes-Enrollment-in-Feasibility-Study-of-RNS-System-for-Lennox-Gastaut-Syndrome.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NPCE","BK4086","BK4539","IDE","BK4082","LII"],"gpt_icon":0},{"id":"2485256403","title":"Strong Buy Recommendation for NeuroPace Amid Promising RNS System Results and Anticipated Market Advancements","url":"https://stock-news.laohu8.com/highlight/detail?id=2485256403","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485256403?lang=en_us&edition=fundamental","pubTime":"2024-11-22 19:35","pubTimestamp":1732275325,"startTime":"0","endTime":"0","summary":"NeuroPace (NPCE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Vik Chopra from Wells ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/strong-buy-recommendation-for-neuropace-amid-promising-rns-system-results-and-anticipated-market-advancements?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/strong-buy-recommendation-for-neuropace-amid-promising-rns-system-results-and-anticipated-market-advancements?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","BK4539","NPCE"],"gpt_icon":0},{"id":"2484602195","title":"What Makes NeuroPace (NPCE) a New Buy Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2484602195","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484602195?lang=en_us&edition=fundamental","pubTime":"2024-11-19 01:00","pubTimestamp":1731949210,"startTime":"0","endTime":"0","summary":"NeuroPace, Inc.  could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 . An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.Therefore, the Zacks rating upgrade for NeuroPace basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UPInF06X6fJkTqeimnpZuQ--~B/aD03NDU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UPInF06X6fJkTqeimnpZuQ--~B/aD03NDU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/makes-neuropace-npce-buy-stock-170010622.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NPCE","BK4082","BK4539"],"gpt_icon":0},{"id":"2483878279","title":"NeuroPace Third Quarter 2024 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2483878279","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483878279?lang=en_us&edition=fundamental","pubTime":"2024-11-14 18:23","pubTimestamp":1731579825,"startTime":"0","endTime":"0","summary":"NasdaqGM:NPCE Earnings and Revenue Growth November 14th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 10%. Earnings per share  also surpassed analyst estimates by 31%.Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US.The company's shares are up 17% from a week ago.You still need to take note of risks, for example - NeuroPace has   3 warning signs   we think you should be aware of.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neuropace-third-quarter-2024-earnings-102345628.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NPCE"],"gpt_icon":0},{"id":"2483846958","title":"NeuroPace’s Strong Q3 Performance and Growth Potential Earns Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2483846958","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483846958?lang=en_us&edition=fundamental","pubTime":"2024-11-14 15:39","pubTimestamp":1731569957,"startTime":"0","endTime":"0","summary":"NeuroPace (NPCE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on November 12. Analyst Mike Kratky from ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/neuropaces-strong-q3-performance-and-growth-potential-earns-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/neuropaces-strong-q3-performance-and-growth-potential-earns-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NPCE"],"gpt_icon":0},{"id":"2483483260","title":"NeuroPace Is Maintained at Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2483483260","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483483260?lang=en_us&edition=fundamental","pubTime":"2024-11-14 01:29","pubTimestamp":1731518940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NPCE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2024 12:29 ET (17:29 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NPCE"],"gpt_icon":0},{"id":"2483886776","title":"Neuropace Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483886776","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483886776?lang=en_us&edition=fundamental","pubTime":"2024-11-13 22:23","pubTimestamp":1731507828,"startTime":"0","endTime":"0","summary":"Neuropace Inc reports results for the quarter ended September 30 - Earnings SummaryNeuropace Inc NPCE.OQ reported a quarterly adjusted loss of 19 cents per share for the quarter ended September 30, hi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nL8N3MK1N7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NPCE"],"gpt_icon":0},{"id":"2483727070","title":"NeuroPace price target lowered to $13 from $15 at Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2483727070","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483727070?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:16","pubTimestamp":1731496575,"startTime":"0","endTime":"0","summary":"Wells Fargo lowered the firm’s price target on NeuroPace (NPCE) to $13 from $15 and keeps an Overweight rating on the shares. The firm notes the co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neuropace-price-target-lowered-to-13-from-15-at-wells-fargo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neuropace-price-target-lowered-to-13-from-15-at-wells-fargo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NPCE"],"gpt_icon":0},{"id":"2483723200","title":"Neuropace Inc :  Wells Fargo Cuts Target Price to $13 From $15","url":"https://stock-news.laohu8.com/highlight/detail?id=2483723200","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483723200?lang=en_us&edition=fundamental","pubTime":"2024-11-13 18:49","pubTimestamp":1731494978,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nFWN3MK0VR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4082","NPCE"],"gpt_icon":0},{"id":"2483026678","title":"NeuroPace Inc (NPCE) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2483026678","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483026678?lang=en_us&edition=fundamental","pubTime":"2024-11-13 15:18","pubTimestamp":1731482301,"startTime":"0","endTime":"0","summary":"For the complete transcript of the earnings call, please refer to the full earnings call transcript.NeuroPace Inc  reported a record revenue of $21.1 million for Q3 2024, marking a 28% increase compared to the same period last year.The company demonstrated disciplined operating expense management, reducing cash burn to $1.8 million for the quarter.NeuroPace Inc  increased its cash balance from $55.5 million at the end of Q2 to $56.8 million at the end of Q3, indicating strong financial health.The company successfully expanded its market penetration and utilization of both the RNS system and Dixie Medical products.Gross margin for Q3 2024 was 73.2%, slightly down from 74.5% in the same quarter of 2023.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neuropace-inc-npce-q3-2024-071821889.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NPCE"],"gpt_icon":0},{"id":"2483136670","title":"NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483136670","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483136670?lang=en_us&edition=fundamental","pubTime":"2024-11-13 07:00","pubTimestamp":1731452415,"startTime":"0","endTime":"0","summary":"NeuroPace, Inc.  came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.28 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 26.92%. A quarter ago, it was expected that this company would post a loss of $0.29 per share when it actually produced a loss of $0.26, delivering a surprise of 10.34%.NeuroPace , which belongs to the Zacks Medical - Instruments industry, posted revenues of $21.06 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 8.95%. This compares to year-ago revenues of $16.43 million. The company has topped consensus revenue estimates four times over the last four quarters.NeuroPace shares have lost about 29.4% since the beginning of the year versus the S&P 500's gain of 25.8%.While NeuroPace has underperformed the market so far this year, the question that comes to investors' mi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Fj4TPQveJWuth16WIsEVAw--~B/aD01OTQ7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/46ebfcbff417ac1bbde85ad33fa0d4be","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Fj4TPQveJWuth16WIsEVAw--~B/aD01OTQ7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/46ebfcbff417ac1bbde85ad33fa0d4be"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neuropace-inc-npce-reports-q3-230015874.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NPCE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neuropace.com","stockEarnings":[{"period":"1week","weight":-0.0397},{"period":"1month","weight":0.1888},{"period":"3month","weight":0.4398},{"period":"6month","weight":0.5928},{"period":"1year","weight":0.0747},{"period":"ytd","weight":0.032}],"compareEarnings":[{"period":"1week","weight":-0.0349},{"period":"1month","weight":-0.0032},{"period":"3month","weight":0.0268},{"period":"6month","weight":0.0767},{"period":"1year","weight":0.2347},{"period":"ytd","weight":0.2335}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. The company's RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip leads and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.786194},{"month":2,"riseRate":0.666667,"avgChangeRate":0.056638},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.075542},{"month":4,"riseRate":0.333333,"avgChangeRate":0.013657},{"month":5,"riseRate":0,"avgChangeRate":-0.213522},{"month":6,"riseRate":0.75,"avgChangeRate":-0.016224},{"month":7,"riseRate":0.5,"avgChangeRate":0.006484},{"month":8,"riseRate":0.5,"avgChangeRate":0.252418},{"month":9,"riseRate":0.25,"avgChangeRate":-0.113789},{"month":10,"riseRate":0,"avgChangeRate":-0.156102},{"month":11,"riseRate":0.5,"avgChangeRate":0.04289},{"month":12,"riseRate":0.75,"avgChangeRate":0.021017}],"exchange":"NASDAQ","name":"NeuroPace Inc.","nameEN":"NeuroPace Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NeuroPace Inc.(NPCE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NeuroPace Inc.(NPCE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NeuroPace Inc.,NPCE,NeuroPace Inc.股票,NeuroPace Inc.股票老虎,NeuroPace Inc.股票老虎国际,NeuroPace Inc.行情,NeuroPace Inc.股票行情,NeuroPace Inc.股价,NeuroPace Inc.股市,NeuroPace Inc.股票价格,NeuroPace Inc.股票交易,NeuroPace Inc.股票购买,NeuroPace Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NeuroPace Inc.(NPCE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NeuroPace Inc.(NPCE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}